Verona Pharma Plc (VRNA) has released an update to notify the public and investors about its officers.
On January 31, 2024, Rishi Gupta resigned as a non-executive director of Verona Pharma plc, with no disagreements cited regarding company operations. Subsequently, Michael Austwick was appointed as a non-executive director, effective February 1, 2024, with an annual retainer of £40,000. Austwick was granted an option to purchase 144,000 Ordinary Shares at the fair market value, which will vest over a period contingent on his continued service on the Board.
For further insights into VRNA corporate activity, check out TipRanks’ Insiders Trading Activity page.
For a comprehensive understanding of the announcement, you can read the full document here.
